Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CSO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 310,460 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 339,030 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 310,460 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 71,487 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 71,487 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT II | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,962 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,962 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust for Chldn. | 180,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 180,000 F1: As investment trustee of trusts for the benefit of the reporting person's children. |
| Common StockSEC Table I · non-derivative | Indirectby 2024 GRAT II | 101,988 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 101,988 |
| Common StockSEC Table I · non-derivative | Indirectby Children | 56,048 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 56,048 |
Filing footnotes · ownership attribution and instrument terms
F1: As investment trustee of trusts for the benefit of the reporting person's children.
F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 57,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · by 2018 GRAT Disclosed balance after: 0 Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $486.31 | $3,404.17 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 29 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,799 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F24 · balance_after: Form one of two Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,693 | $485.63 | $822,171.59 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 28 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,806 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F23 · price: Represents volume-weighted average price of sales of 1,693 shares of Company stock on March 10, 2020 at prices ranging from $485.12 to $485.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 345 | $484.72 | $167,228.40 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 27 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,499 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F22 · price: Represents volume-weighted average price of sales of 345 shares of Company stock on March 10, 2020 at prices ranging from $484.72 to $484.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 355 | $483.80 | $171,749.00 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 26 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,844 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F21 · price: Represents volume-weighted average price of sales of 355 shares of Company stock on March 10, 2020 at prices ranging from $483.78 to $483.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $481.68 | $48,168.00 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 25 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,199 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 60 | $480.34 | $28,820.40 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 24 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,299 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,651 | $479.60 | $791,819.60 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 23 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,359 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F20 · price: Represents volume-weighted average price of sales of 1,651 shares of Company stock on March 10, 2020 at prices ranging from $479.00 to $479.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,469 | $478.43 | $702,813.67 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 22 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,010 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F19 · price: Represents volume-weighted average price of sales of 1,469 shares of Company stock on March 10, 2020 at prices ranging from $478.09 to $478.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,735 | $477.50 | $2,260,962.50 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 21 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,479 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · price: Represents volume-weighted average price of sales of 4,735 shares of Company stock on March 10, 2020 at prices ranging from $477.00 to $477.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,197 | $476.51 | $3,429,442.47 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 20 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,214 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 7,197 shares of Company stock on March 10, 2020 at prices ranging from $476.02 to $476.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,223 | $475.43 | $2,007,740.89 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 19 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 535,411 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 4,223 shares of Company stock on March 10, 2020 at prices ranging from $475.06 to $475.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,060 | $474.52 | $3,350,111.20 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 18 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,634 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 7,060 shares of Company stock on March 10, 2020 at prices ranging from $474.04 to $474.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,024 | $473.39 | $3,798,481.36 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 17 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,694 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 8,024 shares of Company stock on March 10, 2020 at prices ranging from $473.02 to $473.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,270 | $472.56 | $4,853,191.20 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 16 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,718 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 10,270 shares of Company stock on March 10, 2020 at prices ranging from $472.02 to $472.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,258 | $471.34 | $2,478,305.72 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 15 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,988 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 5,258 shares of Company stock on March 10, 2020 at prices ranging from $471.00 to $471.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,531 | $470.48 | $2,602,224.88 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 14 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,246 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 5,531 shares of Company stock on March 10, 2020 at prices ranging from $470.05 to $470.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,250 | $469.46 | $3,403,585.00 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 13 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,777 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 7,250 shares of Company stock on March 10, 2020 at prices ranging from $469.03 to $469.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,542 | $468.49 | $4,001,841.58 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 12 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,027 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 8,542 shares of Company stock on March 10, 2020 at prices ranging from $468.01 to $468.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,023 | $467.53 | $4,686,053.19 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,569 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 10,023 shares of Company stock on March 10, 2020 at prices ranging from $467.00 to $467.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11,916 | $466.58 | $5,559,767.28 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,592 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 11,916 shares of Company stock on March 10, 2020 at prices ranging from $466.02 to $466.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,068 | $465.45 | $3,289,800.60 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,508 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 7,068 shares of Company stock on March 10, 2020 at prices ranging from $465.08 to $465.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,099 | $464.59 | $2,368,944.41 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,576 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 5,099 shares of Company stock on March 10, 2020 at prices ranging from $464.09 to $464.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,463 | $463.54 | $2,532,319.02 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,675 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 5,463 shares of Company stock on March 10, 2020 at prices ranging from $463.04 to $463.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,317 | $462.43 | $1,533,880.31 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,138 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 3,317 shares of Company stock on March 10, 2020 at prices ranging from $462.02 to $462.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,159 | $461.79 | $535,214.61 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,455 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,159 shares of Company stock on March 10, 2020 at prices ranging from $461.12 to $461.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 10, 2020 at each separate price. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000022 · edgardoc.xml · derivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 96,736 underlying shares, the option award vested in four equal annual installments, commencing one year after the date of grant; and with respect to 150,000 underlying shares, the option became exercisable on December 31, 2013, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2013. F3 · balance_after: Form two of two Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 96,736 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000022 · edgardoc.xml · derivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 96,736 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 96,736 underlying shares, the option award vested in four equal annual installments, commencing one year after the date of grant; and with respect to 150,000 underlying shares, the option became exercisable on December 31, 2013, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2013. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 78,376 | $476.42 | $37,339,893.92 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,614 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 150,000 | $30.63 | $4,594,500.00 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 50,545 | $476.42 | $24,080,648.90 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,990 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 96,736 | $30.63 | $2,963,023.68 |
DisclosureSEC source: 0001708138-20-000021 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 118,123 | $420.17 | $49,631,740.91 |
DisclosureSEC source: 0001237899-20-000012 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,799 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 118,123 shares of Company stock on February 24, 2020 at prices ranging from $420.00 to $420.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 24, 2020 at each separate price. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · derivative · entry 20 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The option became exercisable on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 95,295 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · derivative · entry 19 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 95,295 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 77,767 | $377.16 | $29,330,601.72 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,109 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 150,000 | $21.25 | $3,187,500.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 49,405 | $377.16 | $18,633,589.80 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,876 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 95,295 | $21.25 | $2,025,018.75 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantPerformance Stock Units · Derivative | 25,155 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · derivative · entry 22 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,155 Underlying: Common Stock · 25,155 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. F8 · derivative.exercise_date: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. F8 · derivative.expiration_date: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 81,278 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · derivative · entry 21 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,278 Underlying: Common Stock · 81,278 shares Expires 2029-12-11 F7 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 18, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftClass A Stock · Derivative | 23,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · derivative · entry 16 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 23,367 shares Expires not disclosed F2 · derivative.exercise_price: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. F3 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F3 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. Read SEC document |
| November 18, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftClass A Stock · Derivative | 23,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · derivative · entry 15 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,367 Underlying: Common Stock · 23,367 shares Expires not disclosed F2 · derivative.exercise_price: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. F3 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F3 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. Read SEC document |
| November 18, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 325,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 13 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 Read SEC document |
| November 18, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 325,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,986 Read SEC document |
| November 14, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 12 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 325,989 Read SEC document |
| August 05, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 75,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 328,352 Read SEC document |
| August 05, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 75,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by 2017 GRAT Disclosed balance after: 0 Read SEC document |
| June 13, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 253,316 Read SEC document |
| June 13, 2019 Filed Dec 13, 2019 21:44 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000930413-19-003028 · ownership.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by 2019 GRAT Disclosed balance after: 500,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.